Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients

BACKGROUND: Nivolumab combined with ipilimumab have shown activity in melanoma brain metastasis (MBM). However, in most of the clinical trials investigating immunotherapy in this subgroup, patients with symptomatic MBM and/or prior local brain radiotherapy were excluded. We studied the efficacy of n...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaral, Teresa, Kiecker, Felix, Schaefer, Sarah, Stege, Henner, Kaehler, Katharina, Terheyden, Patrick, Gesierich, Anja, Gutzmer, Ralf, Haferkamp, Sebastian, Uttikal, Jochen, Berking, Carola, Rafei-Shamsabadi, David, Reinhardt, Lydia, Meier, Friedegund, Karoglan, Ante, Posch, Christian, Gambichler, Thilo, Pfoehler, Claudia, Thoms, Kai, Tietze, Julia, Debus, Dirk, Herbst, Rudolf, Emmert, Steffen, Loquai, Carmen, Hassel, Jessica C, Meiss, Frank, Tueting, Thomas, Heinrich, Vanessa, Eigentler, Thomas, Garbe, Claus, Zimmer, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206917/
https://www.ncbi.nlm.nih.gov/pubmed/32221017
http://dx.doi.org/10.1136/jitc-2019-000333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206917/
https://www.ncbi.nlm.nih.gov/pubmed/32221017
http://dx.doi.org/10.1136/jitc-2019-000333

Ejemplares similares